Skip to main content

Advertisement

SpringerLink
Log in

Effekt der Dosissteigerung von Infliximab bei rheumatoider Arthritis

Effect of increasing the infliximab dose in rheumatoid arthritis

  • Klinische Studien kurzgefasst
  • Published:
Zeitschrift für Rheumatologie Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. van Vollenhoven RF (2009) Editorial: How to dose infliximab in rheumatoid arthritis: new data on a serious issue. Ann Rheum Dis 68:1237–1239; doi:10.1136/ard.2009.111682

    Article  Google Scholar 

  2. Maini R, St Clair EW, Breedveld F et al (1999) Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354:1932–1939

    Article  CAS  PubMed  Google Scholar 

  3. Lipsky PE, van der Heijde DM, St Clair EW et al (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343:1594–1602

    Article  CAS  PubMed  Google Scholar 

  4. St Clair EW, van der Heijde DM, Smolen JS et al (2004) Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 50:3432–3443

    Article  Google Scholar 

  5. Durez P, Van den Bosch F, Corluy L et al (2005) A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective study. Rheumatology (Oxford) 44:465–468

    Google Scholar 

  6. St Clair EW, Wagner CL, Fasanmade AA et al (2002) The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46:1451–1459

    Article  Google Scholar 

  7. van Vollenhoven RF, Brannemark S, Klareskog L (2004) Dose escalation of infliximab in clinical practice: improvements seen may be explained by a regression-like effect. Ann Rheum Dis 63:426–430

    Article  Google Scholar 

  8. Finckh A, Simard JF, Gabay C, Guerne PA (2006) Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis. Ann Rheum Dis 65:746–752

    Article  CAS  PubMed  Google Scholar 

  9. van Vollenhoven RF, Klareskog L (2007) Infliximab dosage and infusion frequency in clinical practice: experiences in the Stockholm biologics registry STURE. Scand J Rheumatol 36:418–423

    Article  Google Scholar 

  10. Ariza-Ariza R, Navarro-Sarabia F, Hernández-Cruz B et al (2007) Dose escalation of the anti-TNF-alpha agents in patients with rheumatoid arthritis. A systematic review. Rheumatology (Oxford) 46:529–532

    Google Scholar 

  11. Flendrie M, Creemers MC, van Riel PL (2007) Titration of infliximab treatment in rheumatoid arthritis patients based on response patterns. Rheumatology (Oxford) 46:146–149

    Google Scholar 

  12. Rahman MU, Strusberg I, Geusens P et al (2007) Double-blinded infliximab dose escalation in patients with rheumatoid arthritis. Ann Rheum Dis 66:1233–1238

    Article  CAS  PubMed  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. Abt. Innere Medizin II (Hämatologie, Onkologie, Immunologie, Rheumatologie, Pulmologie), Medizinische Universitätsklinik, Otfried-Müller-Str. 10, 72076, Tübingen, Deutschland

    M. Schmalzing

Authors
  1. M. Schmalzing
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Schmalzing.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schmalzing, M. Effekt der Dosissteigerung von Infliximab bei rheumatoider Arthritis. Z. Rheumatol. 69, 450–453 (2010). https://doi.org/10.1007/s00393-009-0557-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00393-009-0557-9

Search

Navigation